SEATTLE, WA — (BUSINESS WIRE)– October 16, 2017– Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced planned poster presentations highlighting recent data at the following scientific meetings:
Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
- Abstract Title: Novel Immuno-Oncology Biologics Derived via Directed Evolution of IgSF Domains
- Abstract #: P343
- Session Title: Immune Modulation, Cytokines, and Antibodies
- Location: National Harbor, MD
- Date: November 10, 2017
40th Annual San Antonio Breast Cancer Symposium (SABCS)
- Abstract Title: ICOSL Anti-HER2 V-mAbs: Localizing Engineered ICOSL Costimulatory Agonists to HER2+ tumors through Trastuzumab
- Abstract #: P1-09-10
- Session Title: Treatment: Novel Targets and Targeted agents
- Location: San Antonio, TX
- Date: December 6, 2017
- Time: 5:00 PM – 7:00 PM CT
American Society of Hematology (ASH) 59th Annual Meeting
- Abstract Title: Novel Variant Ig Domain (vIgD) Proteins Generated Via Directed Evolution of IgSF Domains Have Therapeutic Efficacy in Animal Models of Graft Versus Host Disease
- Abstract #: 1892
- Session Title: Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster I
- Location: Atlanta, GA
- Date: December 9, 2017
- Time: 5:30 PM – 7:30 PM ET
The Company previously announced its planned poster presentation at the 2017 American College of Rheumatology Annual Meeting.
- Abstract Title: A Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain™ (vIgD) Potently Suppresses Mouse Collagen Induced Arthritis and Human Xenograft Graft Vs. Host Disease (GvHD)
- Abstract #: 1328
- Session Title: Rheumatoid Arthritis – Animal Models Poster II
- Location: San Diego, CA
- Date: November 6, 2017
- Time: 9:00 AM – 11:00 AM PT
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is focused on developing novel protein-based immunotherapies using its proprietary Variant Ig Domain (vIgD) platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which produces proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to cancer, autoimmune, and inflammatory diseases. Alpine has also developed Transmembrane Immunomodulatory Protein (TIP) technology, based on the vIgD platform, to potentially enhance engineered cellular therapies. For more information visit www.alpineimmunesciences.com
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact, and include statements regarding Alpine’s platform technology and potential therapies. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “intend,” and other similar expressions among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: Alpine’s discovery-stage and pre-clinical programs may not advance into the clinic or result in approved products on a timely or cost-effective basis or at all; Alpine may not achieve additional milestone payments pursuant to its collaborations; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in Alpine’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Alpine undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
“Transmembrane Immunomodulatory Protein,” “TIP,” “Variant Ig Domain,” “vIgD” and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.
Pure Communications, Inc.
Courtney Dugan, 212-257-6723
Jennifer Paganelli, 347-658-8290